Part 1: Background, methodology, and clinical adoption of pharmacogenetics

Oncologist

Volumn 16, Issue 6, 2011, Pages 811-819

  Deenen, Maarten J ^a,b   Cats, Annemieke ^c   Beijnen, Jos H ^d,e   Schellens, Jan H M ^a,b,e  

^a Department of Pharmacochemistry   (Netherlands)

^b Department of Experimental Therapy ^*  (Netherlands)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

^d SLOTERVAART HOSPITAL   (Netherlands)

^e UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Anticancer drugs; Genotyping technologies; Oncology; Pharmacogenetics

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; CETUXIMAB; CYCLOPHOSPHAMIDE; DNA; FLUOROURACIL; IFOSFAMIDE; IRINOTECAN; MELPHALAN; PANITUMUMAB; PLATINUM COMPLEX; TAMOXIFEN; TEGAFUR;

ARTICLE; BREAST CANCER; DRUG EFFECT; DRUG METABOLISM; DRUG RESPONSE; DRUG TRANSPORT; EPIGENETICS; GENE MUTATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; PERSONALIZED MEDICINE; PHARMACODYNAMICS; PHARMACOGENETICS; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIGENOMICS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; MUTATION; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 79959608477     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2010-0258     Document Type: Article

References (59)

1. Brookes AJ. The essence of SNPs. Gene 1999;234:177-186.
2. Sachidanandam R, Weissman D, Schmidt SC et al. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 2001;409:928-933.
3. Sebat J, Lakshmi B, Troge J et al. Large-scale copy number polymorphism in the human genome. Science 2004;305:525-528.
4. Nebert DW. Suggestions for the nomenclature of human alleles: Relevance to ecogenetics, pharmacogenetics and molecular epidemiology. Pharmaco-genetics 2000;10:279-290.
5. Sauna ZE, Kimchi-Sarfaty C, Ambudkar SV et al. Silent polymorphisms speak: How they affect pharmacogenomics and the treatment of cancer. Cancer Res 2007;67:9609-9612.
6. Yu JJ, Lee KB, Mu C et al. Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene. Int J Oncol 2000;16:555-560.
7. Yu JJ, Mu C, Lee KB, etal. A nucleotide polymorphism inERCC1inhuman ovarian cancer cell lines and tumor tissues. Mutat Res 1997;382:13-20.
8. Isla D, Sarries C, Rosell R et al. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol 2004;15:1194-1203.
9. Ruzzo A, Graziano F, Loupakis F et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol 2007;25:1247-1254.
10. Ryu JS, Hong YC, Han HS et al. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer 2004;44: 311-316.
11. Redon R, Ishikawa S, Fitch KR, et al. Global variationincopy numberinthe human genome. Nature 2006;444:444-454.
12. Stranger BE, Forrest MS, Dunning M et al. Relative impact of nucleotide and copy number variation on gene expression phenotypes. Science 2007; 315:848-853.
13. Dahl ML, Johansson I, Bertilsson L et al. Ultrarapid hydroxylation of de-brisoquine in a Swedish population. Analysis of the molecular genetic basis. J Pharmacol Exp Ther 1995;274:516-520.
14. Johansson I, Lundqvist E, Bertilsson L, et al. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci U S A 1993;90:11825-11829.
15. Pemble S, Schroeder KR, Spencer SR et al. Human glutathione S-trans-ferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism. Biochem J 1994;300:271-276.
16. Seidegård J, Vorachek WR, Pero RW, et al. Hereditary differences in the expression of the human glutathione transferase active on trans-stilbene oxide are due to a gene deletion. Proc Natl Acad Sci U S A 1988;85:7293-7297.
17. Marsh S, Mallon MA, Goodfellow P et al. Concordance of pharmacoge-netic markers in germline and colorectal tumor DNA. Pharmacogenomics 2005;6:873-877.
18. Marsh S. Pharmacogenomics. Ann Oncol 2007;18(suppl 9):ix24-ix28.
19. Amado RG, Wolf M, Peeters M et al. Wild-type KRAS is required for pa-nitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-1634.
20. Karapetis CS, Khambata-Ford S, Jonker DJ et al. K-ras mutations and benefit from cetuximabin advanced colorectal cancer. N EnglJ Med 2008;359: 1757-1765.
21. Bird A. Perceptions of epigenetics. Nature 2007;447:396-398.
22. Jones PA, Takai D. The role of DNA methylation in mammalian epigenet-ics. Science 2001;293:1068-1070.
23. Evans WE, McLeod HL. Pharmacogenomics-drug disposition, drug targets, and side effects. N Engl J Med 2003;348:538-549.
24. Swen JJ, Wilting I, de Goede AL et al. Pharmacogenetics: From bench to byte. Clin Pharmacol Ther 2008;83:781-787.
25. Goetz MP, Rae JM, Suman VJ et al. Pharmacogenetics of tamoxifen bio-transformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 2005;23:9312-9318.
26. Schroth W, Antoniadou L, Fritz P et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol 2007;25:5187-5193.
27. Wegman P, Vainikka L, Stal O et al. Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res 2005;7:R284-R290.
28. Deenen MJ, Cats A, Beijnen JH et al. Pharmacogenetic variability in drug transport and phase I anticancer drug metabolism. The Oncologist 2011; 16:820-834.
29. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 1992;43:329-339.
30. Gardiner SJ, Begg EJ, Barclay ML et al. Genetic polymorphism and outcomes with azathioprine and 6-mercaptopurine. Adverse Drug React Toxi-col Rev 2000;19:293-312.
31. Otterness D, Szumlanski C, Lennard L et al. Human thiopurine methyl-transferase pharmacogenetics: Gene sequence polymorphisms. Clin Pharmacol Ther 1997;62:60-73.
32. Spire-Vayron de la Moureyre, Debuysère H, Sabbagh N, et al. Detection of known and new mutations in the thiopurine S-methyltransferase gene by single-strand conformation polymorphism analysis. Hum Mutat 1998;12: 177-185.
33. Tai HL, Krynetski EY, Yates CR et al. Thiopurine S-methyltransferase deficiency: Two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am J Hum Genet 1996;58:694-702.
34. Tai HL, Krynetski EY, Schuetz EG et al. Enhanced proteolysis of thiopu-rine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): Mechanisms for the genetic polymorphism of TPMT activity. Proc Natl Acad Sci U S A 1997;94:6444-6449.
35. Yates CR, Krynetski EY, Loennechen T et al. Molecular diagnosis of thio-purine S-methyltransferase deficiency: Genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997;126:608-614.
36. McLeod HL, Coulthard S, Thomas AE et al. Analysis of thiopurine meth-yltransferase variant alleles in childhood acute lymphoblastic leukaemia. Br J Haematol 1999;105:696-700.
37. Relling MV, Hancock ML, Rivera GK et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 1999;91:2001-2008.
38. Stanulla M, Schaeffeler E, Flohr T et al. Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. JAMA 2005;293:1485-1489.
39. Ulrich CM, Robien K, McLeod HL. Cancer pharmacogenetics: Polymorphisms, pathways and beyond. Nat Rev Cancer 2003;3:912-920.
40. Efferth T, Volm M. Pharmacogenetics for individualized cancer chemotherapy. Pharmacol Ther 2005;107:155-176.
41. Hoehe MR, Timmermann B, Lehrach H. Human inter-individual DNA sequence variation in candidate genes, drug targets, the importance of haplo-types and pharmacogenomics. Curr Pharm Biotechnol 2003;4:351-378.
42. Johnson RC, Nelson GW, Troyer JL et al. Accounting for multiple comparisons in a genome-wide association study (GWAS). BMC Genomics 2010;11:724.
43. Burmester JK, Sedova M, Shapero MH, et al. DMET microarray technology for pharmacogenetic-based personalized medicine. Methods Mol Biol 2010;632:99-124.
44. Pearson TA, Manolio TA. How to interpret a genome-wide association study. JAMA 2008;299:1335-1344.
45. Yang JJ, Cheng C, Yang W et al. Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukaemia. JAMA 2009;301:393-403.
46. Nemer M. Genetic insights into normal and abnormal heart development. Cardiovasc Pathol 2008;17:48-54.
47. Rosner S, Giladi N, Orr-Urtreger A. Advances in the genetics of Parkinson's disease. Acta Pharmacol Sin 2008;29:21-34.
48. El Omar EM, Ng MT, Hold GL. Polymorphisms in Toll-like receptor genes and risk of cancer. Oncogene 2008;27:244-252.
49. Roses AD. Pharmacogenetics and the practice of medicine. Nature 2000; 405:857-865.
50. Lascorz J, Försti A, Chen B et al. Genome-wide association study for colo-rectal cancer identifies risk polymorphisms in German familial cases and implicates MAPK signalling pathways in disease susceptibility. Carcino-genesis 2010;31:1612-1619.
51. Watson MA, Stewart RK, Smith GB, et al. Human glutathione S-transferase P1 polymorphisms: Relationship to lung tissue enzyme activity and population frequency distribution. Carcinogenesis 1998;19:275-280.
52. Saxena R, Shaw GL, Relling MV, et al. Identification of a new variant CYP2D6 allele with asingle base deletion in exon3and its association with the poor metabolizer phenotype. Hum Mol Genet 1994;3:923-926.
53. Meinsma R, Fernandez-Salguero P, Van Kuilenburg AB, et al. Human polymorphism in drug metabolism: Mutation in the dihydropyrimidine dehy-drogenase gene results in exon skipping and thymine uracilurea. DNA Cell Biol 1995;14:1-6.
54. Mandola MV, Stoehlmacher J, Zhang W, et al. A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. Pharmacogenetics 2004;14:319-327.
55. Ulrich CM, Bigler J, Velicer CM et al. Searching expressed sequence tag databases: Discovery and confirmation of a common polymorphism in the thymidylate synthase gene. Cancer Epidemiol Biomarkers Prev 2000;9: 1381-1385.
56. Sim SC, Risinger C, Dahl ML et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 2006;79: 103-113.
57. Beutler E, Gelbart T, Demina A. Racial variability in the UDP-glucuronosyl-transferase 1 (UGT1A1) promoter: A balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci U S A 1998;95:8170-8174.
58. Bosma PJ, Chowdhury JR, Bakker C et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 1995;333:1171-1175.
59. Abdel-Rahman SZ, el Zein RA, Anwar WA et al. A multiplex PCR procedure for polymorphic analysis of GSTM1 and GSTT1 genes in population studies. Cancer Lett 1996;107:229-233.